UK markets open in 3 hours 50 minutes
  • NIKKEI 225

    27,628.73
    -518.78 (-1.84%)
     
  • HANG SENG

    28,042.21
    -188.83 (-0.67%)
     
  • CRUDE OIL

    65.52
    -0.56 (-0.85%)
     
  • GOLD FUTURES

    1,819.00
    -3.80 (-0.21%)
     
  • DOW

    33,587.66
    -681.50 (-1.99%)
     
  • BTC-GBP

    35,584.67
    -5,226.18 (-12.81%)
     
  • CMC Crypto 200

    1,374.52
    -189.31 (-12.11%)
     
  • ^IXIC

    13,031.68
    -357.75 (-2.67%)
     
  • ^FTAS

    3,986.82
    +23.84 (+0.60%)
     

Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.

  • Oops!
    Something went wrong.
    Please try again later.
·6-min read
  • Oops!
    Something went wrong.
    Please try again later.

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous
19.04.2021 / 07:00

Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.

Geneva, Switzerland, April 19, 2021 -
RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), commented today on certain statements made by NeuroRx, Inc., its collaboration partner for the development of RLF-100TM (aviptadil) pursuant to that certain binding collaboration agreement, dated September 18, 2020 (the "Collaboration Agreement"), in Amendment No. 1 to the Form S-4 of Big Rock Partners Acquisition Corp.'s ("BPRA") that was filed on Friday, April 16, 2021 (the "Amendment"). The Amendment was filed by BRPA with respect to the proposed merger between NeuroRx and BRPA.

NeuroRx has elected to make statements in the Amendment with respect to pending disputes between Relief and NeuroRx under the terms of the Collaboration Agreement. As a result, Relief has concluded that it must inform the public about the nature of the pending disputes and its views regarding the positions regarding these issues taken by its collaboration partner. The issues currently in dispute include the following:

Relief intends to continue its efforts to resolve amicably the pending disputes with NeuroRx over the Collaboration Agreement. However, if such disputes are not resolved amicably, Relief intends to take all necessary actions to enforce its rights under the Collaboration Agreement. While there can be no assurance, Relief believes that it will prevail in any such actions to enforce its rights under the Collaboration Agreement.

ABOUT RELIEF THERAPEUTICS HOLDING AG
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com.

Follow us on LinkedIn

CONTACT:
RELIEF THERAPEUTICS Holding AG

Raghuram (Ram) Selvaraju, Ph.D., MBA                                            
Chairman of the Board
Mail: contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG

Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, including the outcome of the pending disputes between Relief and NeuroRx if such disputes are not resolved amicably, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


End of Media Release

Language:

English

Company:

RELIEF THERAPEUTICS Holdings AG

Avenue de Sécheron 15

1202 Genève

Switzerland

E-mail:

contact@relieftherapeutics.com

Internet:

https://relieftherapeutics.com

ISIN:

CH0100191136

Listed:

SIX Swiss Exchange

EQS News ID:

1185949


 

End of News

EQS Group News Service

show this
show this